In chronic myeloid leukemia cells, the interaction between STAP-2 and BCR-ABL is crucial in conferring growth advantages, resistance to imatinib (a BCR-ABL inhibitor), and tumor progression [11]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.